The global diabetic ketoacidosis treatment market size is expected to reach US$ 3.5 Billion in 2022 and exhibit growth at a CAGR of 5.7% in the forecast period from 2022 to 2032. It is anticipated to surpass US$ 6.8 Billion in 2032. The rising prevalence of diabetes, especially type 1 diabetes globally is a major factor that is set to propel the demand for diabetic ketoacidosis treatment options.
Report Attribute
Details
Diabetic Ketoacidosis Treatment Market Estimated Base Year Value (2021)
US$ 2.1 Billion
Diabetic Ketoacidosis Treatment Market Expected Market Value (2022)
US$ 3.5 Billion
Diabetic Ketoacidosis Treatment Market Anticipated Forecast Value (2032)
Diabetic ketoacidosis is a life-threatening complication that occurs with diabetes. It is a very common condition in patients suffering from type 1 diabetes. It leads to the buildup of acids in the patient’s blood.
Headache, dry mouth, frequent peeing, fatigue, less alertness, nausea, belly pain, and muscle aches are some of the first symptoms of this condition. It happens when an individual’s body doesn’t have adequate insulin.
When the cells are incapable of using sugar in the blood for generating energy, they start using fuel and fats instead. The burning of fats often creates ketones, which can eventually change the blood’s chemical balance and disrupt the entire system.
The increasing focus of many manufacturers on the development of cost-effective treatment options for this condition is likely to spur the market. In January 2020, for instance, Eli Lilly and Company announced that it is planning to launch two new cost-saving insulin solutions. Similar other product launches are expected to bode well for the market.
Which are Some Prominent Drivers Spearheading Diabetic Ketoacidosis Treatment Market Growth?
The high demand for more efficient technologies and drugs for the treatment and management of diabetic ketoacidosis is projected to bolster the market in the evaluation period. The increasing awareness about the availability of various unique products for the treatment of this condition is another crucial factor that is anticipated to bode well for the diabetic ketoacidosis treatment market growth.
The rising number of several pharmaceutical companies in both developed and developing countries is also likely to drive the market. The rapid adoption of novel treatment facilities by numerous medium and small healthcare centers, as well as hospitals is estimated to spur the growth.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What are the Challenges Faced by the Diabetic Ketoacidosis Treatment Industry?
The lack of advanced treatment options and awareness about diabetic ketoacidosis in emerging economies may obstruct the market in the assessment period. Adverse side effects associated with the treatment of this condition can also hamper the graowth.
Adjustment of the blood sugar level at a rapid pace by using insulin and fluids can cause swelling in the brain. At the same time, it can lead to impair activities of the nervous system, muscles, and heart, as well as a drop in potassium level in the blood.
Besides, the requirement of constant monitoring of insulin levels and the unavailability of skilled healthcare professionals in remote areas are anticipated to negatively affect the sales of diabetic ketoacidosis treatment options. The limited availability of innovative facilities in multiple healthcare centers and hospitals can hinder the market.
Why is North America emerging as an Opportunistic Diabetic Ketoacidosis Treatment Market?
The rising cases of diabetes among the population in Canada and the U.S. are projected to fuel the North America diabetic ketoacidosis treatment market share. According to the Centers for Disease Control and Prevention (CDC), in the U.S., nearly 37.3 million people have diabetes and 8.5 million adults are undiagnosed. These numbers are estimated to surge in the future years, thereby driving the North America market.
The presence of favorable reimbursement scenarios and the increasing awareness regarding the early diagnosis of this condition are likely to accelerate the market. The availability of cutting-edge treatment options and the entrance of several renowned companies in this region are also set to propel the market.
Find your sweet spots for generating winning opportunities in this market.
How is Asia Pacific Contributing to Growth of the Diabetic Ketoacidosis Treatment Market?
Asia Pacific is expected to remain in the second position and exhibit a steady diabetic ketoacidosis treatment market growth. The rising incidence of type 1 diabetes and the surging adoption of sedentary lifestyles are projected to augur well for the market.
The high geriatric population and the increasing adoption of effective strategies by leading companies based in China and India are some of the other crucial factors that are likely to aid the growth. The surging usage of insulin therapy backed by the ongoing advancement in the field of insulin delivery technique is another factor that is likely to augment the regional market.
Market Competition
Some of the prominent companies operating in the global diabetic ketoacidosis treatment market include Merck & Co., Inc., Novo Nordisk A/S, Eli Lilly and Company, Biocon Limited, Wockhardt Ltd., Sanofi S.A., Bristol Myers Squibb, Tonghua Dongbao Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Oramed Pharmaceuticals Inc., and Pfizer Inc. among others.
Some of the leading players are engaging in partnerships and collaborations with renowned companies to co-develop new treatment options and gain fast track approvals from regulatory bodies. Meanwhile, a few other players are increasingly focusing on broadening their existing product portfolios and expanding their geographic presence to fulfill the high unmet demand worldwide.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 5.7% from 2022 to 2032
Base Year for Estimation
2021
Historical Data
2015-2020
Forecast Period
2022-2032
Quantitative Units
Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Treatment Type
Application
End User
Region
Regions Covered
North America
Latin America
Western Europe
Easter Europe
APEJ
Japan
Middle East & Africa
Key Countries Profiled
U.S
Canada
Brazil
Argentina
Germany
U.K
France
Spain
Italy
Nordics
BENELUX
Australia & New Zealand
China
India
ASEAN
GCC
South Africa
Key Companies Profiled
Merck & Co., Inc.
Novo Nordisk A/S
Eli Lilly and Company
Biocon Limited
Wockhardt Ltd.
Sanofi S.A.
Bristol Myers Squibb
Tonghua Dongbao Pharmaceutical Co., Ltd.
GlaxoSmithKline plc
Oramed Pharmaceuticals Inc.
Pfizer Inc.
Customization
Available Upon Request
Key Segments Profiled in the Diabetic Ketoacidosis Treatment Industry Survey
By Treatment Type:
Insulin Therapy
Fluid Replacement
Electrolyte Replacement
By Application:
Pediatric
Adults
By End User:
Specialty Clinics
Ambulatory Care Center
Hospitals
By Region:
North America
Latin America
Western Europe
Easter Europe
APEJ
Japan
Middle East & Africa
Frequently Asked Questions
At what rate will the diabetic ketoacidosis treatment market grow?
The global diabetic ketoacidosis treatment market is estimated to exceed US$ 6.8 Billion by 2032.
Which region is expected to dominate the diabetic ketoacidosis treatment market?
North America is expected to dominate the diabetic ketoacidosis treatment market.
Which are some of the leading companies in the diabetic ketoacidosis treatment market?
Merck & Co., Inc., Novo Nordisk A/S, Eli Lilly and Company, Biocon Limited, Wockhardt Ltd., Sanofi S.A., and Bristol Myers Squibb are some of the leading companies in the diabetic ketoacidosis treatment market.
